BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther 2019;44:495-507. [PMID: 30873648 DOI: 10.1111/jcpt.12830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Byun HG, Jang M, Yoo HK, Potter J, Kwon TS. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom. Appl Health Econ Health Policy 2021;19:735-45. [PMID: 34383287 DOI: 10.1007/s40258-021-00673-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rezk MF, Pieper B. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Adv Ther 2020;37:3732-45. [PMID: 32740789 DOI: 10.1007/s12325-020-01437-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Han H, Sun W, Feng L, Wen Z, Yang M, Ma Y, Fu J, Ma X, Xu X, Wang Z, Yin T, Wang XM, Lu GH, Qi JL, Lin H, Yang Y. Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis. PeerJ 2021;9:e10675. [PMID: 33505807 DOI: 10.7717/peerj.10675] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ding Z, Obando C, Muser E, Kozma C, Slaton T. Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USA. Drugs Real World Outcomes 2021. [PMID: 34136998 DOI: 10.1007/s40801-021-00264-5] [Reference Citation Analysis]
7 Sriram A, Tangirala S, Atmakuri S, Hoque S, Modani S, Srivastava S, Mahajan S, Maji I, Kumar R, Khatri D, Madan J, Singh PK. Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech 2021;22:264. [PMID: 34734325 DOI: 10.1208/s12249-021-02133-4] [Reference Citation Analysis]
8 Dutcher SK, Eworuke E, Blum MD, Ball R. Using real-world data to evaluate biosimilar switching. Pharmacoepidemiol Drug Saf 2020;29:814-6. [PMID: 31692176 DOI: 10.1002/pds.4899] [Reference Citation Analysis]
9 Seow CH, Targownik LE. Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes. Aliment Pharmacol Ther 2019;50:603-4. [PMID: 31414536 DOI: 10.1111/apt.15421] [Reference Citation Analysis]
10 Larussa T, Suraci E, Marasco R, Imeneo M, Abenavoli L, Luzza F. Self-Prescribed Dietary Restrictions are Common in Inflammatory Bowel Disease Patients and Are Associated with Low Bone Mineralization. Medicina (Kaunas) 2019;55:E507. [PMID: 31434334 DOI: 10.3390/medicina55080507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Li-Wan-Po A, Peterson GM. Drug compliance and the Morisky Adherence Scale: An expression of concern and a warning. J Clin Pharm Ther 2021;46:1-3. [PMID: 33285010 DOI: 10.1111/jcpt.13325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease. Biologics 2021;15:237-45. [PMID: 34163137 DOI: 10.2147/BTT.S310076] [Reference Citation Analysis]
13 Wang L, Fan R, Zhang C, Hong L, Zhang T, Chen Y, Liu K, Wang Z, Zhong J. Applying Machine Learning Models to Predict Medication Nonadherence in Crohn's Disease Maintenance Therapy. Patient Prefer Adherence. 2020;14:917-926. [PMID: 32581518 DOI: 10.2147/ppa.s253732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
16 Stewart MJ, Bessissow T, Gregor J, Hazel M, In TSH, Karra K, Dajnowiec D, Williamson M, Sattin B. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 2021;38:4115-29. [PMID: 34159558 DOI: 10.1007/s12325-021-01818-3] [Reference Citation Analysis]